Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A. Palma, Suresh Senan, Robert Olson et al.|The Lancet|2019Cited by 1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialDavid A. Palma, Suresh Senan, Liam Mulroy et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysisDavid A. Palma, George Rodrigues, Suresh Senan et al.|International Journal of Radiation Oncology*Biology*Physics|2013Cited by 673
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung CancerA. Ashworth, George Rodrigues, Suresh Senan et al.|Clinical Lung Cancer|2014Cited by 437
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trialDavid A. Palma, Suresh Senan, Cornelis J.A. Haasbeek et al.|BMC Cancer|2012Cited by 308